Approximately 20% of all new breast cancers diagnosed in the United States are ductal carcinoma in situ (DCIS),1 and no two DCIS patients—or their tumors—are the same.
A pre-invasive form of breast cancer in which tumor cells are confined within the milk ducts, DCIS is typically non-lethal but treatments—such as surgery, radiation therapy, and hormonal therapy—can cause both short term and long-term side effects.
Exact Sciences’ Oncotype DX Breast DCIS Score® test enables women and their doctors to personalize their treatment decisions and potentially forgo unnecessary treatment, such as radiation, when they have a low score and a low risk of local recurrence. For those with higher scores, the result confirms that they would indeed benefit from a more aggressive local approach to treatment, such as radiation therapy.
